ROIV vs. ALNY, TEVA, GMAB, RPRX, BGNE, BMRN, VTRS, UTHR, SRPT, and RDY
Should you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical preparations" industry.
Roivant Sciences (NASDAQ:ROIV) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.
Alnylam Pharmaceuticals received 1048 more outperform votes than Roivant Sciences when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 75.00% of users gave Roivant Sciences an outperform vote.
Roivant Sciences has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.
In the previous week, Roivant Sciences had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 7 mentions for Roivant Sciences and 6 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.28 beat Roivant Sciences' score of 1.10 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.
Roivant Sciences presently has a consensus price target of $16.90, suggesting a potential upside of 56.63%. Alnylam Pharmaceuticals has a consensus price target of $216.19, suggesting a potential upside of 41.56%. Given Roivant Sciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Roivant Sciences is more favorable than Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 4.6% of Roivant Sciences shares are owned by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Roivant Sciences has a net margin of 3,624.14% compared to Alnylam Pharmaceuticals' net margin of -16.58%. Alnylam Pharmaceuticals' return on equity of 0.00% beat Roivant Sciences' return on equity.
Summary
Roivant Sciences and Alnylam Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Roivant Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roivant Sciences Competitors List
Related Companies and Tools
